Exagen Inc. XGN
5.04 USD -0.22 (-4.28%)
At closeNov 11, 2026, 4:00 PM EST
4.93 -0.11 -2.09%
After hours · Nov 11, 4:00 PM ET
4.69 Day range 5.64
2.59 52-week range 9.74
- YTD
- -17.19%
- 1 year
- -45.39%
News
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.
marketbeat.com What Exagen (XGN) Said on Its Q3 Earnings Call Exagen NASDAQ: XGN reported third-quarter revenue of $18.4 million, up 7% from a year earlier, as higher test volume and pricing helped the autoimmune diagnostics company post what management…
seekingalpha.com Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript Exagen Inc. (XGN) Q3 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imaging
zacks.com Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates Exagen Inc. (XGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.19 per share a year ago.
benzinga.com Exagen Q3 2026 Earnings Call Transcript Exagen (NASDAQ:XGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Exagen Affirms FY2026 Sales Guidance of $72.000M-$75.000M vs $73.886M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $72.000 million-$75.000 million to $72.000 million-$75.000 million vs $73.886 million estimate.- benzinga.com Exagen Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $18.417M Beat $18.343M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 31.58 percent decrease over losses of $(0.19) per…
globenewswire.com Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) --…
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.- benzinga.com TD Cowen Maintains Buy on Exagen, Raises Price Target to $11 TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.